Shattuck Labs, Inc. (NASDAQ:STTK) Director Acquires $11,700.00 in Stock

Shattuck Labs, Inc. (NASDAQ:STTK) Director Tyler Brous bought 3,000 shares of the company’s stock in a transaction that occurred on Friday, June 28th. The stock was purchased at an average price of $3.90 per share, with a total value of $11,700.00. Following the transaction, the director now directly owns 238,088 shares in the company, valued at $928,543.20. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Shattuck Labs Price Performance

NASDAQ STTK opened at $3.64 on Wednesday. Shattuck Labs, Inc. has a 1 year low of $1.33 and a 1 year high of $11.76. The stock has a market capitalization of $173.09 million, a PE ratio of -1.89 and a beta of 1.85. The business’s 50-day moving average is $7.48 and its 200 day moving average is $8.39.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.08. Shattuck Labs had a negative return on equity of 64.85% and a negative net margin of 3,133.63%. The company had revenue of $1.15 million during the quarter, compared to analyst estimates of $0.30 million. The company’s revenue was up 2200.0% compared to the same quarter last year. As a group, equities research analysts anticipate that Shattuck Labs, Inc. will post -1.56 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Cannon Global Investment Management LLC bought a new position in shares of Shattuck Labs during the first quarter valued at $91,000. Virtu Financial LLC purchased a new stake in Shattuck Labs during the 1st quarter valued at about $113,000. Tower Research Capital LLC TRC increased its stake in Shattuck Labs by 79.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 13,553 shares of the company’s stock valued at $97,000 after purchasing an additional 5,989 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new position in Shattuck Labs in the first quarter worth about $174,000. Finally, Reliant Investment Management LLC bought a new position in shares of Shattuck Labs in the fourth quarter worth approximately $143,000. 58.74% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

STTK has been the topic of a number of analyst reports. Citigroup decreased their target price on shares of Shattuck Labs from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday, June 17th. HC Wainwright lowered their target price on Shattuck Labs from $28.00 to $16.00 and set a “buy” rating for the company in a research note on Thursday, June 20th. BTIG Research lowered Shattuck Labs from a “buy” rating to a “neutral” rating in a research report on Monday, June 17th. Finally, Needham & Company LLC lowered their price objective on Shattuck Labs from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, June 14th.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.